EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Insulet Corp. (PODD) announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s (ABT) FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the United States. The latest development represents a significant step forward in the company’s efforts to expand access to its innovative, tubeless Omnipod 5 AID System for more people.In August 2024, the FDA cleared Omnipod 5 for use by people with type 2 diabetes (18 years and above), expanding the technolog ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I last covered the insulin pump maker Insulet (NASDAQ: PODD ) in a note for Seeking Alpha back in June, noting the company's stock price had recovered from a devastating be ...

Insulet Corporation (PODD) reported third-quarter 2024 adjusted earnings per share (EPS) of 90 cents, up significantly 26.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 16.9%.GAAP EPS was $1.08, up 45.9% from the year-ago figure of 74 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, PODD’s share price surged 2.9% to $275.7 yesterday.PODD’s Q3 RevenuesRevenues totaled $543.9 million, which beat t ...

28 February 2019, Berlin: A remote control (PDM) for the tubeless insulin pump of the type mylife ... [+] Omnipod is located on a math book when solving math tasks. Measuring blood sugar levels regularly is essential in the treatment of diabetes. Photo: Jens Kalaene/dpa-Zentralbild/ZB (Photo by Jens Kalaene/picture alliance via Getty Images)picture alliance via Getty ImagesInsulet stock (NASDAQ: PODD) surged nearly 10% on Friday, November 8, after the company posted an upbeat Q3 and raised its sales outlook ...

Insulet Corporation (NASDAQ:PODD) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President of Investor Relations Jim Hollingshead - President and Chief Executive Officer Ana Maria Chadwick - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Robert Marcus - JPMorgan Jeffrey Johnson - Baird Travis Steed - Bank of America Michael Polark - Wolfe Research Danielle Antalffy - UBS Patrick Wood - Morgan Stanley Lawre ...

| --- | --- | --- | |--------------------|-------------------|-------| | | | | | | Mattie | | | | Podder since 2010 | | | Q3'24 Earnings | | | | November 7, 2024 | | | This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimate ...

Insulet (PODD) reported $543.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 25.7%. EPS of $0.90 for the same period compares to $0.71 a year ago.The reported revenue represents a surprise of +4.90% over the Zacks Consensus Estimate of $518.5 million. With the consensus EPS estimate being $0.77, the EPS surprise was +16.88%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Insulet (PODD) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.88%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $0.57 per share when it actually produced earnings of $0.55, delivering a surprise of -3.51%.Over the last four quar ...

Table of Contents _____________________________________________________ ________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q _____________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF T ...